Product Description
Cebranopadol is a novel first-in-class analgesic with highly potent agonistic activity at nociceptin/orphanin FQ peptide (NOP) and opioid receptors. It is highly potent and efficacious across a broad range of preclinical pain models. Its side effect profile is better compared to typical opioids. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30927089/)
Mechanisms of Action: OPR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Tris Pharma
Company Location: Eastern America
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Acute Pain
Phase 1: Healthy Volunteers|Substance Abuse Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06453265 |
TRN-228-102 | P1 |
Completed |
Healthy Volunteers|Substance Abuse Unspecified |
2024-11-06 |
88% |
2025-09-06 |
|
NCT06423703 |
ALLEVIATE2 | P3 |
Completed |
Acute Pain |
2025-01-31 |
16% |
2026-01-09 |
Primary Endpoints |
NCT06545097 |
ALLEVIATE1 | P3 |
Completed |
Acute Pain |
2024-12-30 |
14% |
2026-01-09 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |